

28/04/2026

ROE remains high

Pension line supportive; investment gains slightly up

Anadolu Hayat reported 1Q26 net income of TL1,661mn (-7% q/q, +59% y/y), in line with both our estimate (TL1,681mn) and market consensus (TL1,667mn). On the technical profitability side, on a q/q basis, the pension segment contributed more to profitability than the life segment. Pension AUM grew by 7% q/q, while technical profitability surged by 139% q/q. In contrast, life insurance premiums declined by 7% q/q, and technical income from the life segment fell by 33%. Investment income also supported the results, increasing by 2% q/q (+296% y/y). Trailing ROE improved q/q to 56% in 1Q, compared to 54% in 4Q and 50% a year ago. We expect 28% earnings growth from ANHYT in 2026 with a ROE of 49%.

MP rating maintained

Anadolu Hayat trades at 26E P/BV of 2.9x and 6.7x P/E, while 26E ROE stands at 49%. Our 12M TP for ANHYT implies 32% upside potential. We maintain our "Marketperform" recommendation for the stock.

ANHYT - 1Q26 Earnings Review					
TLmn	1Q25	4Q25	1Q26	ΔQ/Q	ΔY/Y
Life premiums	4,395	6,116	5,676	-7%	29%
Pension contributions	9,580	18,478	18,919	2%	97%
Pension AUM	227,922	355,825	380,384	7%	67%
Life - Tech. net income	621	1,231	827	-33%	33%
Pension - Tech. net income	182	78	185	139%	2%
Net income	1,043	1,790	1,661	-7%	59%
Life - Technical NIM (%)	14.1	20.1	14.6	-5.6	0.4
Pension - Technical NIM (%)	1.9	0.4	1.0	0.6	-0.9
Technical NIM (%)	5.7	5.3	4.1	-1.2	-1.6
NIM (%)	7.5	7.3	6.8	-0.5	-0.7
Four Quarter Trailing ROE (%)	50	54	56	2.4	6.8

* NIM stand for net income margin; changes are in pp for ratios

ANHYT TI / ANHYT.IS

Current Rating		Marketperform	
Expected Market Reaction	⇒	Neutral	
Analyst Action	⇒	None	
Price	TL111.10	Mcap (mnTL)	47,773
Target Price	TL146.60	Mcap (mn\$)	1,062
Upside	32%	Prev. Target Price	TL138.30
High /Low 30Day	126 / 105	Free Float	15%

BB 2026FY Consensus

Estimate Revisions	1W	4W	3M
EPS	0.0%	0.0%	0.0%
# of Buy/Hold/Sell	5/1/0	5/1/0	6/0/0
Rel Perf. XU030	0.7%	-17.9%	-11.8%
ADV (USDmn)	2.5	2.7	3.3

OYAK vs BB consensus

(26E TLmn)	OYAK	Cons.	% Diff
NI	7,179	5,105	41%

Multiples & Ratios

(OYAK Est)	2024	2025	2026E
P/E	11.74x	8.53x	6.65x
P/B	4.94x	3.71x	2.94x
RoE	51.0%	49.7%	49.3%
(TLmn)	2024	2025	2026E
Net income	4,070	5,599	7,179
Equity	9,676	12,864	16,246

Analyst: Övünç Gürsoy, PhD, CFA

Disclaimer

The information, comments and advices included herein do not constitute an offer or a solicitation of an offer to buy or sell any securities. The matters covered on this report may include forward-looking statements that involve risk and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. OYAK Yatırım Menkul Değerler A.Ş. ("OYAK Securities"), does not undertake to advise you of changes in the information or opinions set forth herein or provide you with access to any additional information or to correct any inaccuracies therein which may become apparent subsequent to the date hereof or to publicly update any information or any forward looking statement, whether as a result of new information, future events or otherwise. Content and information provided by third parties is published as supplied to OYAK Securities and OYAK Securities has not independently verified any of such information.

The investment information, comments and advices given herein are not part of investment advisory activity. Investment advisory services are provided by authorized institutions to persons and entities privately by considering their risk and return preferences. Whereas the comments and advices included herein are of general nature. Therefore, they may not be appropriate for your financial situation and risk and return preferences. For this reason, making an investment decision solely by relying on the information given herein may not give rise to results within your expectations. Investors should not make their investment decisions on the basis of this report and construe the contents of this report as legal, tax, financial or investment advice.

OYAK Securities, any of its parents, subsidiaries or affiliates, agents, employees or representatives, do not make any representations or warranties, express or implied, for the accuracy, timeliness, completeness or fairness of any such information or any estimates, conclusions or opinions based thereon, and does not accept any liability or responsibility whatsoever for the contents of the report or for any errors, omissions or mis-statements or for any adverse consequences of the investment decisions made as a result of reliance upon this report.

OYAK Securities, any of its parents, subsidiaries or affiliates, agents, employees or representatives may hold positions and execute transactions in securities of entities mentioned in the document. In addition, OYAK Securities, any of its parents, subsidiaries or affiliates, agents, employees or representatives might have, might be seeking or will seek investment banking or other business relationships with the companies in this report.

Copyright in this report is owned by OYAK Securities except where otherwise indicated by a third party's proprietary notice and may not be reproduced or appropriated in any manner without written permission of OYAK Securities or their respective owners.

Valuation Approach

Valuation tools employed most frequently are Discounted Cash Flow (DCF) and International Peer Group Comparison, though other metrics such as Dividend Discount, Gordon Growth, and Replacement Value Methods are also used wherever appropriate. Oyak Securities analysts may calculate the target return of each stock considering only one method or assigning different weights to more than one method depending on the analyst's opinion. The "Expected Market Return" (**EMR**) of the BIST-100 is determined through aggregate target returns of each stock under coverage based on their respective free float market capitalization.

Rating Methodology

Oyak Securities assigns recommendations to each stock according to the following criteria:

Price target for a stock represents the value analyst expects the stock to reach during our performance horizon, which is 12 months. For stocks with an OUTPERFORM recommendation, target return must exceed the EMR by at least 40% over the next 12 months. For a stock to be classified as UNDERPERFORM, the stock must be expected to underperform the EMR more than 25% over the next 12 months. Stocks that an analyst expects to perform parallel to the EMR within a band of +40%/-25% are rated as MARKETPERFORM. Oyak Securities analysts review their recommendations under continuous screening. Nevertheless, at times, target return of a stock may be allowed to move outside our rating intervals as a result of share price fluctuations. Under such circumstances, the analyst may choose not to change his/her recommendation.